{"filings":[{"id":1278798,"accession_number":"0001104659-26-077820","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2026-06-25T21:00:40+00:00","items":["5.07"],"status":"ready","headline":"Gain Therapeutics elects seven directors, ratifies auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Mack, Goldstein, Hasler, Islam, Melincoff, Nicaise, Riley; each received >13.5M votes.","Ratification of Ernst & Young AG as independent auditor for FY 2026 approved with ~25.9M for, 1.1M against.","Broker non-votes of ~11.7M shares on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":651356,"accession_number":"0001104659-26-066062","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2026-05-26T13:26:00+00:00","items":["8.01"],"status":"ready","headline":"Gain Therapeutics reports Phase 1b extension: GluSph down 81%, 4.8-pt MDS-UPDRS difference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["16 of 19 Part 1 participants continued into 9-month extension; all 16 remain on study at Day 150.","In participants with elevated baseline CSF GluSph, levels dropped an average of 81% after 90 days.","At Day 150, high-baseline GluSph group showed 4.8-point greater improvement in MDS-UPDRS Parts II+III vs low-baseline group.","Unsolicited patient reports: improved smell/taste (4), balance/gait (4), and sleep (3) after 90 days.","Planned Phase 2 will add UPSIT smell test and Opal wearable gait assessments as endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12883,"accession_number":"0001104659-26-058636","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2026-05-11T20:05:35+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Q1 net loss $0.13/sh; Phase 1b biomarker data support GT-02287","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $0.13 per share vs $0.16; R&D $2.8M, G&A $2.6M; cash $16.5M as of March 31, 2026.","Phase 1b extension for GT-02287 shows GluSph in CSF decreased 81% in elevated baseline participants after 90 days.","MDS-UPDRS scores stable over 150 days; 14 of 16 participants completed five months of dosing as of March 2026.","Expecting FDA IND clearance for GT-02287 in Q2 2026 and Phase 2 start in Q3 2026.","New allosteric modulator GT-04686 ready for IND-enabling studies; presented at AD/PD 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109063,"accession_number":"0001104659-26-035174","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics FY2025 net loss $20.2M ($0.61/sh); cash $20.8M; Phase 1b data supports GT-02287","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.2M ($0.61 per share) vs $20.4M ($0.89) prior year; R&D $10.2M, G&A $8.5M.","Cash, equivalents & marketable securities $20.8M as of Dec 31, 2025 (up from $10.4M).","Phase 1b extension: 14 of 16 participants completed day 150; MDS-UPDRS scores stable.","CSF GluSph decreased 81% at day 90 in elevated-baseline participants; DDC also reduced.","IND submission for GT-02287 expected 2Q26; Phase 2 start 3Q26; Phase 1b final data 4Q26."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109062,"accession_number":"0001104659-26-029968","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gain Therapeutics presents Phase 1b data showing stable MDS-UPDRS and biomarker improvements for GT-02287 at AD/PD 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b: 19 completed Part 1, 16 entered extension; DMC approved continuation without changes.","MDS-UPDRS scores stable over 150 days; high GluSph group showed 6.7-point difference vs low group.","DDC decreased after 90 days in high GluSph baseline group, supporting disease-modifying potential.","Preclinical data for novel GCase modulator GT-04686 presented, ready for IND-enabling studies.","Extension study expected to complete September 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109061,"accession_number":"0001104659-26-009747","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gain Therapeutics posts updated corporate presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation filed as Exhibit 99.1 on Form 8-K dated February 3, 2026.","Slides describe business overview; only cover page and disclaimer are in filed text.","No financial results, pipeline updates, or guidance disclosed in the exhibit.","Investor presentation routine; no material new information provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125537,"accession_number":"0001104659-25-122353","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gain Therapeutics reports positive exploratory endpoint from Phase 1b study of GT-02287 in Parkinson's Disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GT-02287 reduced elevated GluSph in CSF to near-normal levels after 90 days in Phase 1b study.","19 of 21 enrolled participants completed 90-day dosing; 15 (79%) chose to continue in 9-month extension ending Sept 2026.","Drug well-tolerated; data monitoring committee recommended study continue with no changes.","Company has capital to fund operations through end of Phase 1b extension and year-end 2026.","Phase 1 healthy volunteer study showed favorable safety, target engagement with increased GCase activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125536,"accession_number":"0001104659-25-116947","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Gain Therapeutics files prospectus supplement for up to $35.5M ATM stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement filed for ATM offering of up to $35.5M of common stock via Oppenheimer & Co.","Company previously sold $14.47M under prior ATM program dated Sept 2024, now updating under new shelf.","New S-3 registration (333-287622) became effective Nov 26, 2025; supplement dated Nov 28, 2025.","Proceeds expected for general corporate purposes; legal opinion from Lowenstein Sandler attached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125535,"accession_number":"0001104659-25-110343","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Reports Q3 2025 Results and Phase 1b Data for GT-02287 in Parkinson's Disease","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment of 21 participants in Phase 1b study of GT-02287, surpassing original target of 15.","Initial data from first nine participants showed improvement in MDS-UPDRS scores, suggesting disease-slowing effect.","Received Australian approval to extend Phase 1b dosing to 12 months; ~80% of participants joined extension.","Net loss for Q3 2025 was $0.15 per share; cash and cash equivalents $8.8 million as of September 30, 2025.","R&D expenses increased to $2.8 million from $2.6 million year-over-year, driven by Phase 1b trial costs."],"consensus_eps_estimate":-0.153,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125534,"accession_number":"0001104659-25-099343","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gain Therapeutics hosts KOL event highlighting emerging GT-02287 Parkinson's data","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Virtual KOL event on Oct 14, 2025 featured Dr. Karl Kieburtz (Univ. of Rochester) and Dr. Kenneth Marek (Institute for Neurodegenerative Disorders).","Presentation focused on biomarkers, clinical endpoints, and path to disease modification for GT-02287.","GT-02287 is a GCase-targeting small molecule for Parkinson's disease; emerging data was contextualized.","Slides from the event were furnished as an exhibit; no new quantitative data or financial guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125533,"accession_number":"0001104659-25-098376","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gain Therapeutics director Eric Richman resigns from board without disagreement; board reduced to seven","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Richman resigned from the Board effective October 6, 2025.","Resignation was not due to any disagreement with company operations, policies, or practices.","Board size reduced from eight to seven members on October 7, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125532,"accession_number":"0001104659-25-097153","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gain Therapeutics reports positive Phase 1b data for GT-02287 in Parkinson's disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GT-02287 safe and well-tolerated after 90 days; no serious adverse events.","Transient liver enzyme increases normalized with ongoing dosing.","Mean UPDRS Part II and III scores improved at Day 90, suggesting disease-slowing effect.","Plasma PK consistent across 14 participants, within therapeutic range.","DMC recommended continuation; Australian authorities approved 12-month extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142271,"accession_number":"0001558370-25-011218","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Q2 net loss $0.19/sh; Phase 1b PD study fully enrolled, data by Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 1b of GT-02287 in Parkinson's reached target enrollment in Q2 2025 with 16 patients; up to 20 total.","Functional and biomarker analysis from 90-day dosing expected in Q4 2025; extension request submitted.","Net loss per share $0.19 vs $0.42 YoY; R&D spend down to $2.8M on grant income and credit.","Cash $6.7M as of June 30; July 2025 public offering raised ~$7.1M net, extending runway past Phase 1b.","IND submission to FDA for GT-02287 expected by year-end 2025 to enable US Phase 2 expansion."],"consensus_eps_estimate":-0.1717,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142270,"accession_number":"0001104659-25-068530","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Gain Therapeutics prices $7M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 4,501,640 common shares and warrants to purchase 2,250,820 shares at $3.11 per set.","Gross proceeds of $7.0M; net proceeds expected ~$6.3M after underwriting fees and expenses.","Proceeds to fund clinical development of lead candidate GT-02287 for GBA1 Parkinson's disease.","Warrants exercisable at $1.65 per share, immediately exercisable, expire in 5 years.","Newbridge Securities sole book-runner; closing expected July 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160284,"accession_number":"0001104659-25-064145","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gain Therapeutics Phase 1b for GT-02287 enrolls 16 patients; biomarker data now expected Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment reached 16 participants (target 15-20) despite 2-month protocol delay.","Independent DMC recommends continue study unchanged; no serious adverse events reported.","Faster enrollment means 90-day visit and CSF biomarker results earlier in Q4 2025 vs. Q1 2026.","Screening window extended through July 31, 2025; planning to request dosing extension beyond 90 days in Australia.","Long-term toxicology studies near completion; update on dosing extension expected before end of Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160283,"accession_number":"0001104659-25-062162","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Gain Therapeutics stockholders approve doubling authorized common stock to 100M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to increase authorized common shares from 50M to 100M.","All eight director nominees elected; Ernst & Young AG ratified as auditor for FY2025.","Vote results: 16.3M for share increase, 2.2M against, 12k abstain; 18.0M ratified auditor.","Adjournment proposal also approved to allow further proxy solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160282,"accession_number":"0001558370-25-007744","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Q1 net loss $0.16/share; Phase 1b of GT-02287 enrollment underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.16 (basic/diluted) vs $0.22 prior year; cash $9.1M as of March 31, 2025.","R&D expenses $2.3M (down $0.2M), G&A expenses $2.1M (up $0.2M) compared to Q1 2024.","Phase 1b study of GT-02287 for Parkinson's disease initiated; first biomarker analysis expected mid-2025.","Gene Mack appointed CEO effective Jan 6, 2025; Gianluca Fuggetta assumed SVP Finance and PFO role.","IND submission to FDA expected by year end 2025; Phase 1b completion expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160281,"accession_number":"0001104659-25-033797","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gain Therapeutics Announces Additional Preclinical Data and Phase 1b Study Design for GT-02287 in Parkinson's Disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GT-02287 showed disease-modifying potential in GBA1 and idiopathic Parkinson's disease models, with biomarkers statistically reduced and lasting after drug washout.","Phase 1b study ongoing; early biomarker analysis of enrolled participants expected mid-2025, including GBA1 mutation carriers and non-carriers.","Complete Phase 1b endpoint analysis after 90 days of treatment anticipated in Q4 2025, guiding Phase 2 design in H2 2025.","Oral presentation at AD/PD 2025 highlighted behavioral and biomarker data supporting GT-02287's disease-modifying capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178578,"accession_number":"0001558370-25-003807","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics reports FY2024 net loss $20.4M; Phase 1b dosing initiated for GT-02287","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.4M ($0.89 EPS) vs $22.3M ($1.71 EPS) in FY2023; revenue not reported.","Cash and securities $10.4M at Dec 31, 2024, down from $16.8M a year earlier.","First patient dosed in Phase 1b trial of GT-02287 for Parkinson's disease; first analysis expected Q2 2025.","Gene Mack appointed President and CEO effective Jan 6, 2025; pre-IND engagement with FDA started.","R&D expenses fell to $10.8M and G&A to $9.6M vs $11.5M and $10.8M in FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178577,"accession_number":"0001104659-25-010148","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gain Therapeutics updates on GT-02287 Phase 1b trial for Parkinson's disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b trial of GT-02287 approved; dosing imminent in Australia, enrolling 15-20 patients with GBA1 or idiopathic PD.","Prior healthy volunteer study showed 53% increase in GCase activity and confirmed safety/tolerability.","Cash of $12M as of September 30, 2024, expected to fund operations through interim analysis in 2Q 2025.","FDA pre-IND meeting found no significant regulatory hurdles; IND submission on track for Phase 2 planning in 2H 2025.","Promotion of Gianluca Fuggetta to SVP Finance; company exploring licensing partners and financing options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178576,"accession_number":"0001104659-25-003801","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gain Therapeutics receives and cures Nasdaq MVLS deficiency within days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq MVLS deficiency notice on Jan 8, 2025 for falling below $50M minimum from Nov 14 to Dec 27, 2024.","Regained compliance as of Jan 14, 2025; Nasdaq confirmed compliance in writing on Jan 15, 2025.","No immediate impact on listing; common stock continues trading on Nasdaq Global Market under GANX.","Deficiency was cured within one week; matter is now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178575,"accession_number":"0001104659-25-001711","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Gain Therapeutics appoints Gene Mack as permanent CEO, Fuggetta as Principal Financial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gene Mack, interim CEO since June 2024, appointed President and CEO and Board member effective Jan 6, 2025.","Mack resigns as CFO; receives $500K base salary, 50% target bonus, and option for 271,325 shares at $2.44.","Gianluca Fuggetta, VP of Finance, becomes SVP Finance and Principal Financial Officer; base salary CHF 200K.","Mack brings 25+ years biotech experience; Fuggetta previously served as interim Principal Financial Officer in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195247,"accession_number":"0001104659-24-131084","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gain Therapeutics receives Australian approval to start Phase 1b trial of GT-02287 for Parkinson's disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Australian ethics approval obtained for Phase 1b trial of GT-02287 in GBA1-PD and idiopathic PD patients.","Trial will dose 13.5 mg/kg/day for three months; primary endpoint safety/tolerability; secondary endpoints include biomarkers.","Enrollment expected to complete spring 2025; data anticipated mid-2025.","Phase 1 in healthy volunteers showed safety, CNS exposure, and >50% increase in GCase activity (statistically significant).","Company plans Phase 2 preparation after Phase 1b results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195246,"accession_number":"0001558370-24-015705","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics reports Q3 net loss of $0.17/share; plans Phase 1b start for GT-02287 by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share improved to $0.17 from $0.37 in Q3 2023; R&D spend rose to $2.6M.","Cash and marketable securities $12M as of Sept 30, 2024, down from $16.8M at Dec 31, 2023.","Phase 1 MAD results showed 53% increase in GCase activity; safety and tolerability confirmed.","Initiation of Phase 1b trial in Parkinson's patients expected by end of Q4 2024.","Pre-IND meeting with FDA planned before end of 2024 to support Phase 2 expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195245,"accession_number":"0001104659-24-110287","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Gain Therapeutics regains Nasdaq compliance with $50M market value requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on Oct 21, 2024 confirming regained compliance with MVLS Requirement.","Previously non-compliant as of July 11, 2024; had until Jan 7, 2025 to cure.","Compliance now achieved; matter closed with no further action needed.","Regained compliance ensures continued listing on The Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195244,"accession_number":"0001104659-24-107052","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gain Therapeutics reports preclinical GT-02287 data showing disease-modifying potential in Parkinson's models","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GT-02287 rescued motor and cognitive deficits in GBA1 and idiopathic PD models; effects persisted >1 week after drug withdrawal.","GT-02287 improved mitochondrial function and reduced α-synuclein aggregation in GBA1-PD in vitro and in vivo models.","GT-02287 reduced Tau accumulation in GBA1-mutant and wild-type cell lines, suggesting potential for Alzheimer's disease.","Delayed GT-02287 administration restored motor function to control levels and reduced neurodegeneration markers (NfL)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211499,"accession_number":"0001104659-24-097781","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Gain Therapeutics (GANX) enters $50M at-the-market equity offering with Oppenheimer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity Distribution Agreement allows sale of up to $50M in common stock via Oppenheimer as agent.","Oppenheimer will receive a 3.0% commission on gross proceeds; company also reimburses certain expenses.","Sales will be made under existing shelf registration statement (Form S-3, effective June 1, 2022).","Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.","Shares offered through Nasdaq or other trading market; no escrow or trust arrangement for proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211498,"accession_number":"0001558370-24-011585","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Q2 net loss $0.42/shr; expects MAD Phase 1 topline for GT-02287 in August 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.42 for Q2 2024 vs $0.62 in Q2 2023; cash & securities $16.9M as of June 30, 2024.","Topline results from MAD Phase 1 study of GT-02287 for Parkinson's disease expected in August 2024.","Phase 1b study in Parkinson's patients with/without GBA1 mutation initiation anticipated in Q4 2024.","Gene Mack appointed interim CEO and CFO; Khalid Islam serves as Executive Chairman.","Completed underwritten public offering with approximately $10.0M net proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211497,"accession_number":"0001104659-24-079601","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Gain Therapeutics receives Nasdaq MVLS deficiency notice; must regain compliance by Jan 7, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Gain on June 11, 2024, that MVLS was below $50M minimum required for Global Market listing.","Company has 180 days (through Jan 7, 2025) to achieve MVLS >= $50M for ten consecutive business days.","Failure to comply may lead to delisting; company could appeal or apply to transfer to Nasdaq Capital Market.","Gain intends to monitor and take reasonable measures but cannot assure compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211496,"accession_number":"0001104659-24-078600","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Gain Therapeutics completes MAD dosing for GT-02287 Phase 1; no SAEs, on track for Q4 2024 patient trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed dosing in MAD part of Phase 1 study of GT-02287 for Parkinson's disease; no discontinuations or serious adverse events.","GT-02287 well tolerated up to highest planned dose; 90% of adverse events mild, 10% moderate, no Grade 3+ events.","Topline data expected mid-August after database lock; full safety and PK data to be presented at future congress.","On track to initiate clinical trial in Parkinson's disease patients by Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230165,"accession_number":"0001104659-24-076341","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Gain Therapeutics CEO Alder departs; CFO Mack named interim CEO, Chairman Islam becomes Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Matthias Alder left June 25, 2024 to pursue other opportunities; separation includes 12 months salary, COBRA, accelerated vesting.","CFO Gene Mack appointed interim CEO effective June 25, 2024 and retains CFO role with no additional compensation.","Chairman Khalid Islam, PhD, named Executive Chairman to advise Mack until a permanent CEO is found.","Company's lead candidate GT-02287, an allosteric small molecule for Parkinson's, is in Phase 1 clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230164,"accession_number":"0001104659-24-074822","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Gain Therapeutics stockholders elect eight directors, ratify Ernst & Young as auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; broker non-votes of 5,183,098 shares on each nominee.","Vote totals for directors ranged from 4,308,578 (Hasler) to 6,581,651 (Richman).","Ernst & Young AG ratified as independent auditor for FY2024: 11,836,784 for, 119,833 against, 35,623 abstain.","Meeting held June 24, 2024 with quorum present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230163,"accession_number":"0001104659-24-071801","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Gain Therapeutics prices $11M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 7,116,547 shares at $1.35/share and 1,031,602 pre-funded warrants at $1.3499 each.","Gross proceeds of ~$11M; net proceeds of ~$10.1M after discounts and expenses.","Proceeds to fund clinical development of GT-02287 for GBA1 Parkinson's disease.","Underwriter Titan Partners granted 30-day option for 1,222,222 additional shares (15% over-allotment).","Underwriter warrants for 570,370 shares at $1.6875, exercisable 6 months post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230162,"accession_number":"0001558370-24-008129","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Q1 net loss $0.22/shr; cash $12.7M; GT-02287 Phase 1 SAD positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss per share $0.22 (Q1 2024) vs $0.43 (Q1 2023); narrower loss.","Cash, equivalents & marketable securities $12.7M as of March 31, 2024; cash runway guided into 2025.","R&D expenses $2.5M (down from $2.8M YoY); G&A expenses $1.9M (down from $2.5M YoY).","Positive SAD data for GT-02287; MAD part of Phase 1 initiated for GBA1 Parkinson’s disease.","Appointed Gene Mack as CFO and Jonas Hannestad, M.D., Ph.D. as CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230161,"accession_number":"0001104659-24-044750","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Gain Therapeutics appoints Gene Mack as CFO effective April 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gene Mack appointed CFO; previously CFO at Imcyse SA and OncoC4; over 25 years in life sciences.","Annual base salary $370,000; target cash bonus of 35% of base salary.","Inducement option to purchase 200,000 shares at $3.56, vesting over 4 years with 25% on first anniversary.","Gianluca Fuggetta steps down as principal financial officer but remains VP of Finance and principal accounting officer.","Mack also appointed as Secretary of the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248592,"accession_number":"0001558370-24-003940","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics reports FY2023 net loss of $22.3M; cash runway into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 was $22.3M ($1.71 per share), vs $17.6M ($1.48) in FY2022.","R&D expenses rose to $11.5M from $8.4M due to Phase 1 trial of GT-02287 for GBA1 Parkinson's disease.","Cash and marketable securities $16.8M as of Dec 31, 2023; expected to fund operations into Q1 2025.","Initiated MAD part of Phase 1 trial of GT-02287; data presented at AD/PD 2024 and WORLD Symposium.","Raised $10.1M gross proceeds from public offering and private placement in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248591,"accession_number":"0001104659-24-026302","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gain Therapeutics CFO C. Evan Ballantyne resigns; Gianluca Fuggetta appointed Principal Financial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO C. Evan Ballantyne resigns effective March 1, 2024, departing all positions.","Gianluca Fuggetta, current Senior Director, appointed VP of Finance and Principal Financial Officer from March 1.","Company has initiated a search to identify a new Chief Financial Officer.","Fuggetta previously served as Assurance Manager at PwC; joined Gain in July 2022.","No family relationships or arrangements exist in connection with his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248590,"accession_number":"0001104659-24-008894","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gain Therapeutics CEO provides operational update; Phase 1 trial advancing, cash runway into 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 SAD/MAD trial of GT-02287 underway; MAD cohort expected to start Q1 2024, completion by mid-2024.","$10.1M gross proceeds from Nov 2023 CMPO/PIPE financing; cash runway into 2025 to fund biomarker proof-of-concept.","Computational platform renamed Magellan, now integrates AI/ML and screens 50B+ chemical compounds.","CTO Dr. Xavi Barril leaving; company searching for Chief Medical Officer for clinical development.","Anticipated milestones: MAD completion, Parkinson's patient cohort Q3 2024, biomarker data late 2024/early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266088,"accession_number":"0001104659-23-120819","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Gain Therapeutics prices $9.4M public offering and concurrent private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 2,213,044 shares and 1,106,522 warrants at $2.005/unit; warrants exercisable at $2.75 for 5 years.","Concurrent private placement for $5.0M: common/pre-funded warrants and warrants for 2,500,088 shares at $2.00.","Aggregate gross proceeds $9.4M; net proceeds expected ~$8.35M after fees.","Proceeds to fund GT-02287 development for GBA1 Parkinson's and general corporate purposes.","Newbridge Securities sole underwriter; closing expected Nov 24, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266087,"accession_number":"0001104659-23-119532","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Gain Therapeutics terminates at-the-market offering agreement with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald effective Nov 13, 2023.","Agreement allowed for at-the-market sales; 865,535 shares sold for net proceeds of $3.5M total.","Company gave immediate notice; no reason for termination provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266086,"accession_number":"0001558370-23-019011","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Q3 net loss $4.7M; Phase 1 trial of GT-02287 underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.7M ($0.37/sh) vs $4.6M ($0.38/sh) in Q3 2022; R&D expense rose $0.4M to $2.4M.","Cash, cash equivalents and marketable securities $12.3M; sufficient into Q3 2024.","Phase 1 clinical trial of GT-02287 initiated in Australia; dose escalation ongoing.","Completion of single ascending dose part expected late Q4 2023/early Q1 2024; multiple ascending dose expected Q2 2024.","Preclinical data presented at Parkinson's congress showed GT-02287 reduced NfL biomarker and motor dysfunction."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":55180.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283325,"accession_number":"0001558370-23-014482","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Q2 net loss $7.7M; Phase 1 trial submission for GT-02287","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.7M ($0.62/share) vs $5.1M ($0.43) in Q2 2022, driven by higher R&D and G&A costs.","R&D expenses $4.0M, up $1.4M YoY due to preclinical studies and manufacturing for GBA1 Parkinson's program.","Cash and securities $16.2M; company expects to fund operations into Q3 2024.","Submitted HREC dossier to initiate Phase 1 trial of GT-02287 in Australia in H2 2023.","Late-breaking abstract accepted for presentation at International Congress of Parkinson's Disease."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":55180.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302768,"accession_number":"0001104659-23-074369","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Gain Therapeutics stockholders elect all 8 director nominees, ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected; highest votes for Gwen Melincoff (3,719,922 for), lowest for Hans Peter Hasler (3,491,745 for).","Ernst & Young AG ratified as independent auditor for FY2023 with 7,927,104 votes for, 4,642 against, 11,513 abstentions.","Annual meeting held June 23, 2023; quorum present and all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302767,"accession_number":"0001558370-23-009508","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Q1 net loss widens to $5.1M; cash $18.8M supports ops into Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.1M ($0.43/shr) vs $3.3M ($0.28/shr) YoY; R&D spend rose to $2.8M on pre-IND studies.","Cash and marketable securities $18.8M at March 31, 2023; ATM proceeds in April extend runway into Q3 2024.","Completed GLP toxicology for GT-02287 (GBA1 Parkinson's); Phase 1 application to Australian HREC expected mid-2023.","Secured $2.8M Innosuisse grant for GT-02287 and $1.3M EU consortium grant for AAT program.","Appointed C. Evan Ballantyne as CFO in April 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":55180.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302766,"accession_number":"0001104659-23-052948","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Gain Therapeutics CFO Salvatore Calabrese departs; severance includes pay and equity acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Salvatore Calabrese terminates April 30, 2023; severance includes €249,827 (12 months' salary) and €41,638 bonus.","Unvested equity awards accelerate 100% vesting; options exercisable 12 months after termination.","Additional change-of-control benefits available if triggered before April 30, 2024, less severance paid.","Mutual non-disparagement and cooperation provisions; full release of claims against the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302765,"accession_number":"0001104659-23-044623","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Gain Therapeutics appoints C. Evan Ballantyne as CFO, effective April 10, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment: C. Evan Ballantyne named CFO effective April 10, 2023; predecessor Salvatore Calabrese transitions.","Compensation: $350k base salary, 40% target bonus; inducement equity of 100,000 options at $4.79 (4-year vest) and 100,000 performance RSUs.","Performance RSUs: 50,000 vest upon extending cash runway 24 months; 50,000 vest upon stock price reaching $10.00 for 10 days VWAP.","Background: Ballantyne was CFO of OncXerna, Orchestra BioMed, Cerecin; raised millions in equity and structured >$200M partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322394,"accession_number":"0001558370-23-004458","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics reports FY2022 net loss $17.6M; cash $22.1M; GT-02287 on track for Phase 1 in H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.6M ($1.48/share) vs $13.9M ($1.37) in 2021; R&D spend $8.4M, G&A $9.5M.","Cash and marketable securities $22.1M as of Dec 31, 2022; runway expected into Q2 2024.","GT-02287 IND-enabling studies completed H1 2023; Phase 1 dossier submission by mid-2023; Australian trial in H2 2023.","Awarded €1.2M non-dilutive grant for Alpha-1 Antitrypsin Deficiency research program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340443,"accession_number":"0001104659-22-127798","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gain Therapeutics appoints Gianluca Fuggetta as Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gianluca Fuggetta, Finance Director Corporate Reporting since July 2022, appointed Principal Accounting Officer effective Dec 12, 2022.","Prior to Gain Therapeutics, Fuggetta spent nearly 9 years at PricewaterhouseCoopers, most recently as Assurance Manager.","CFO Salvatore Calabrese, who previously served as both Principal Financial and Accounting Officer, will continue as Principal Financial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340442,"accession_number":"0001558370-22-017407","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gain Therapeutics Q3 net loss $4.56M ($0.38/share); cash $25.7M; CEO promoted; GT-02287 Phase 1 expected mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.56M ($0.38 per share) vs $4.66M ($0.39) in Q3 2021.","Cash, equivalents, and marketable securities $25.7M, providing runway into Q2 2024.","R&D expenses $1.96M (down 21% YoY); G&A $2.79M (up 27% YoY).","Matthias Alder promoted to CEO and appointed to board of directors.","Lead Parkinson's candidate GT-02287 to commence Phase 1 trial in mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":140108.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357717,"accession_number":"0001104659-22-101644","cik":1819411,"company_name":"Gain Therapeutics, Inc.","ticker":"GANX","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Gain Therapeutics appoints Matthias Alder as CEO; Eric Richman resigns effective Sept 20, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Richman resigned as CEO effective Sept 20, 2022; will remain on board through 2023 annual meeting and serve as senior advisor.","Matthias Alder, formerly COO, appointed President and CEO and to a Board seat; receives $500k base salary, 50% target bonus, option for 60,900 shares, and 10,200 RSUs.","Richman entitled to $27,200/month consulting fee for 12 months, plus 329,400 option and 54,900 RSUs vesting on first anniversary.","Board adopted new non-employee director compensation policy: annual cash retainers ($40k board, $7.5k audit, etc.) plus initial option of 21,000 shares and annual award of 10,500 shares.","One-time off-cycle annual option of 10,500 shares granted to each non-employee director on Sept 20, 2022, vesting before next annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":83388642.89830509,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-09-20T23:59:59+00:00|357717"}